Prakash Palde
Director - Biophysics, High Throughput Screening & Oncology Pfizer
Biophysicist swith 15+ years in applying my knowledge and skill to small molecule drug discovery and development. Key areas of experience & expertise include lead generation (DEL, ASMS, Biochem. & Cell HTS, Phenotypic HTS), hit to lead SAR support using biophysical (SPR, Tm Shift, ITC, HTRF) and biochemical assay platforms, proximity platform support for discovery & development of TPD modalities (MGD, PROTACs, Monovalent Degraders), compound management and assay automation, and more recently targeted ADCs payload and bitopics discovery.
Seminars
Effective degrader development relies on precise optimization of key molecular properties to ensure robust, reliable degradation efficiency. Explore how to measure these essential properties, build a process for efficient optimization, and develop a platform to create degraders quickly and reliably. Featuring real-world case studies, this session offers practical strategies to streamline degrader design for maximum therapeutic impact. We will cover:
- The creation of HPB-143/VP-776: an optimized IRAK4 PROTAC modeled against the benchmark KT-474
- Identification and development of BCL-XL protein degraders
- Is ternary complex kinetic stability a key driver of degradation efficiency?
